Given the extensive role of HIF-1 in GBM progression, metabolic adaptation, and therapy resistance, it remains a critical target for novel therapeutic interventions aimed at disrupting tumor survival mechanisms in hypoxic microenvironments. The gene discussed is HIF1A; the disease is glioblastoma.